Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
GLOBAL MED TECHNOLOGIES INC (GLOB)
|
Add to portfolio |
|
|
|
| Price: |
$280.38
| | Metrics |
| OS: |
35.2
|
M
| |
18
|
% ROE
|
| Market cap: |
$9.86
|
B
| |
|
|
|
Net debt:
|
$238
|
k
| |
0.1
|
x Debt/EBITDA
|
|
EV:
|
$9.86
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$4.1
|
M
| |
2392.2
|
x EV/EBITDA
|
|
EBIT
|
$2.7
|
M
| |
3646.3
|
x EV/EBIT
|
| EPS |
$0.00
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
| Date Filed | Type | Description |
| 10/16/2018 |
GN
| Market Trends Toward New Normal in Globant S.A, EZCORP, Earthstone Energy, SPX, Fluidigm, and MAG Silver — Emerging Consolidated Expectations, Analyst Ra...
|
| 08/16/2018 |
GN
| Research Report Identifies Shiloh Industries, Plexus, Haynes International, Aquantia, MarineMax, and Globant S.A with Renewed Outlook — Fundamental Analy...
|
| 05/29/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexi...
|
| 02/14/2011 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/19/2010 |
EFFECT
| Form EFFECT - |
| 04/14/2010 |
4
| DUSTIN WILLIAM SCOTT (Sr VP of Marketing America) has filed a Form 4 on GLOBAL MED TECHNOLOGIES INC |
| 04/14/2010 |
4
| CSORE MIKLOS (Sr VP of Research&Development) has filed a Form 4 on GLOBAL MED TECHNOLOGIES INC |
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| Revenues | 31.8 | 23.4 | 16.1 | 6.9 | 6.5 | 6.6 | 6.2 | 4.4 |
| Revenue growth | 36.0% | 45.3% | | 5.7% | -1.7% | 6.5% | 42.1% | -18.8% |
| Cost of goods sold | 12.7 | 9.2 | 4.9 | 2.4 | 2.3 | 2.1 | 1.9 | 1.0 |
| Gross profit | 19.1 | 14.2 | 11.2 | 4.4 | 4.2 | 4.5 | 4.3 | 3.4 |
| Gross margin | 60.0% | 60.8% | 69.5% | 64.6% | 65.1% | 67.7% | 69.3% | 77.9% |
| Sales and marketing | 4.7 | 3.9 | 2.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.4 |
| Research and development | 4.4 | 3.8 | 3.2 | 0.8 | 0.6 | 0.5 | 0.3 | 0.7 |
| General and administrative | 6.9 | 5.5 | 3.3 | 2.4 | 2.1 | 1.9 | 2.5 | 2.8 |
| EBIT | 2.7 | 0.2 | 1.9 | -0.6 | -0.3 | 0.0 | -0.9 | -2.3 |
| EBIT margin | 8.5% | 0.8% | 11.7% | -8.5% | -4.7% | 0.2% | -14.8% | -52.7% |
| Pre-tax income | 2.0 | -0.1 | 2.1 | -0.8 | -0.9 | -0.7 | -1.7 | -4.9 |
| Income taxes | 0.5 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 26.0% | | 5.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 1.5 | -0.4 | 2.0 | -0.8 | -0.9 | -0.7 | -1.7 | -4.9 |
| Net margin | 4.6% | -1.8% | 12.3% | -11.1% | -13.5% | -10.6% | -27.2% | -111.7% |
| |
| Diluted EPS | $0.00 | $0.00 | $0.05 | ($0.05) | ($0.04) | ($0.03) | ($0.07) | ($0.36) |
| Shares outstanding (diluted) | 44.8 | 29.9 | 42.2 | 15.3 | 22.0 | 23.5 | 24.1 | 13.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|